- Experience:
- 15 years
- Language:
- English
- Location:
- Singapore
Speciality
Expertise
Places of work
Trials Specialist is participating in
4 trials shown
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC in participants with locally re
- Study number:
- NCT05374512
- Cohorts:
- 1
- Study phase:
- 3
- Overall status:
- Recruiting
- Study type:
- Immunotherapy, Chemotherapy
Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer
Primary Objective: To determine whether Amcenestrant (SAR439859) in combination with palbociclib improvesprogression free survival (PFS) when compared with letrozole in combinatio
- Study number:
- NCT04478266
- Cohorts:
- 1
- Study phase:
- 3
- Overall status:
- Active, not recruiting
- Study type:
- Targeted therapy, Hormonal therapy
Astrazeneca
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy in human epidermal growth factor receptor
- Study number:
- NCT04494425
- Cohorts:
- 1
- Study phase:
- 3
- Overall status:
- Recruiting
- Study type:
- Targeted therapy, Biomarker
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or withou
- Study number:
- NCT04269200
- Cohorts:
- 1
- Study phase:
- 3
- Overall status:
- Recruiting
- Study type:
- Immunotherapy, Targeted therapy